Contemporary management of adrenal and retroperitoneal neuroblastoma: current surgical perspectives and emerging molecular biomarkers
Indonesia Journal of Biomedical Science · 10.08.2026 · 20 (2) · 184-171
DOI: 10.15562/ijbs.v20i2.697 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indonesia Journal of Biomedical Science, online erschienen am 10.08.2026. Verfasst von Narpati Wesa Pikatan und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Neuroblastoma is the most common extracranial solid malignancy in children and frequentlyarises from the adrenal gland or retroperitoneal sympathetic chain. Its proximity to the renal hilum, ureter, majorabdominal vessels, and autonomic plexuses creates substantial diagnostic and surgical challenges. Contemporarymanagement therefore requires the integration of anatomic, radiologic, histopathologic, and molecular factors.This narrative review aimed to summarize current surgical principles in adrenal and retroperitoneal neuroblastomaand to examine the emerging role of molecular biomarkers in risk stratification, prognosis, and future therapeuticdevelopment.
Methods
Relevant evidence on clinical presentation, imaging, diagnostic evaluation, risk stratification, surgicalindications, urologic complications, and molecular biomarkers was narratively reviewed. Particular attentionwas given to image-defined risk factors, MYCN amplification, ALK alterations, ploidy, segmental chromosomalabnormalities, telomere maintenance mechanisms, liquid biopsy, and microRNA dysregulation.
Results
Current evidence supports maximal safe resection within a multidisciplinary, risk-adapted treatmentstrategy rather than radical excision at the expense of major morbidity. Image-defined risk factors, especiallyvascular encasement and a high cumulative burden, are associated with more difficult surgery, incompleteresection, and increased perioperative complications. Established biomarkers, including MYCN amplification,ALK alterations, ploidy, and segmental chromosomal abnormalities, remain central to biologic risk assessment.Emerging biomarkers, such as telomere maintenance signatures, circulating tumor-derived markers, and selectedmicroRNAs, may further refine prognostication and treatment selection. The miR-17-92 cluster, miR-34a, miR-101, let-7e, and miR-202 are particularly relevant because of their involvement in MYCN regulation, proliferation,apoptosis, invasion, and clonogenic growth.
Conclusion
Management of adrenal and retroperitoneal neuroblastoma should combine precise surgicaljudgment with biologically informed risk assessment. Future integration of molecular biomarkers, particularlyliquid biopsy and microRNA profiles, may improve patient selection, surveillance, and the development of targetedtherapies while reducing renal, vascular, neurologic, and endocrine morbidity.
Zitieren
APA
Pikatan, N. W., Brodjonegoro, S. R., Moeljono, A., & Kurniawan, W. (2026). Contemporary management of adrenal and retroperitoneal neuroblastoma: current surgical perspectives and emerging molecular biomarkers. Indonesia Journal of Biomedical Science, 20(2), 184-171. https://doi.org/10.15562/ijbs.v20i2.697
Vancouver
Pikatan NW, Brodjonegoro SR, Moeljono A, Kurniawan W. Contemporary management of adrenal and retroperitoneal neuroblastoma: current surgical perspectives and emerging molecular biomarkers. Indonesia Journal of Biomedical Science. 2026;20(2):184-171. doi:10.15562/ijbs.v20i2.697
BibTeX
@article{Pikatan2026,
author = {Pikatan, Narpati Wesa and Brodjonegoro, Sakti Ronggowardhana and Moeljono, Abraham and Kurniawan, Wikan},
title = {Contemporary management of adrenal and retroperitoneal neuroblastoma: current surgical perspectives and emerging molecular biomarkers},
journal = {Indonesia Journal of Biomedical Science},
year = {2026},
volume = {20},
number = {2},
pages = {184--171},
doi = {10.15562/ijbs.v20i2.697}
}
EUVIMED